跳到主要內容

臺灣博碩士論文加值系統

(54.173.214.227) 您好!臺灣時間:2022/01/29 14:43
字體大小: 字級放大   字級縮小   預設字形  
回查詢結果 :::

詳目顯示

我願授權國圖
: 
twitterline
研究生:張韻萍
研究生(外文):Chang Yun-ping
論文名稱:中草藥小金英(Ixerischinensis)對類紅斑性狼瘡小鼠(NZB/NBWF1mice)之影響評估
論文名稱(外文):Evaluation of the Therapeutic Effect of the Chinese Herb Ixeris chinensis on Lupus-like NZB/NZW F1 mice
指導教授:張登欽張登欽引用關係邱繡河
學位類別:碩士
校院名稱:國立中興大學
系所名稱:獸醫微生物學研究所
學門:獸醫學門
學類:獸醫學類
論文種類:學術論文
論文出版年:2002
畢業學年度:90
語文別:中文
論文頁數:69
中文關鍵詞:小金英類紅斑性狼瘡小鼠紅斑性狼瘡
外文關鍵詞:Ixeris chinensisNZB/NBW F1 miceSLE
相關次數:
  • 被引用被引用:2
  • 點閱點閱:1022
  • 評分評分:
  • 下載下載:0
  • 收藏至我的研究室書目清單書目收藏:2
本研究目的是以類紅斑性狼瘡小鼠NZB/NZW F1為動物模式,檢測中草藥小金英(Ixeris chinensis)之藥物效果。將NZB/NZW F1雌鼠分為四組,自小鼠5.5月齡開始發病起每日分別以蒸餾水、類固醇(prednisolone)、小金英煎煮液、類固醇與小金英煎煮液混合灌食,持續灌食9個月,直至小鼠14.5月齡。期間觀測小鼠生長曲線、尿蛋白、介白素-2(interleukin-2)、介白素-4(interleukin-4)、丙型干擾素(interferon-gamma)、抗核抗體(antinuclear antibodies, ANA)及抗雙股去氧核醣核酸(anti-double stranded DNA, anti-dsDNA)抗體等自體抗體力價、腎臟病理變化,並以西方墨漬法作抗核抗體之分析及以血清生化學分析肝腎功能,依據這些指標以評估小金英對類紅斑性狼瘡小鼠之療效。結果以類固醇與小金英煎煮液混合灌食組在自體抗體ANA、anti-dsDNA抗體的力價明顯降低(p<0.01),對於腎臟也有較佳之保護力(p<0.05)。此結果顯示小金英與類固醇併用時,在治療類紅斑性狼瘡小鼠上有部分療效,值得更多研究以評估是否可應用於人的紅斑性狼瘡。
另外在體外試驗中,利用人類T淋巴癌(JKHR-1)細胞株分析小金英對IL-2起動子之影響,由結果得知小金英無法刺激IL-2起動子,也無法抑制由植物性血球凝集素(phytohemaglutinin, PHA)所促進的IL-2生成。而由細胞增殖之試驗發現小金英對JKHR-1細胞有刺激增殖之作用。
The goal of the study is to evaluate the clinical therapeutic effect of the Chinese herb Ixeris chinensis on the lupus-like NZB/NZW F1 female mice. NZB/NZW F1 female mice were divided into four groups. Respectively, each group of mice were force-fed daily with distilled water, prednisolone, I. chinensis decoction, or both I. chinensis decoction and prednisolone. Treatment commenced on the 5.5th month age of NZB/NZW F1 and lasted until the 14.5th month age. Body weight, urine protein, interleukin-2 (IL-2), interleukin-4 (IL-4), interferon-gamma (IFN-g), titer of antinuclear antibodies (ANA), titer of anti-double stranded DNA (anti-dsDNA) antibodies, western analysis for ANA, histopathologic change of glomerulonephritis, and serological biochemical data were analyzed to evaluate the therapeutic effect of each treating group. The data showed that titers of ANA and anti-dsDNA antibodies among mice received both I. chinensis decoction and prednisolone treatment were significantly (p<0.01) lower than that of other groups. Based on histopathologic examination and classification, the same group of mice also showed better protection (p<0.05) from glomerulonephritis. These results indicated that the usage of both I. chinensis and prednisolone might help to reduce disease progression in NZB/NZW mice. However, further study should be made before such treating regimen can be applied in human systemic lupus erythematosus (SLE).
On the other hand, in vitro assay of IL-2 promoter was carried out on human T cell leukemia (JKHR-1). The results showed that I. chinensis decoction neither activated IL-2 promoter nor inhibited IL-2 expression after phytohemaglutinin (PHA) administration. Nevertheless, we observed that I.chinensis decoction could stimulate cell proliferation in JKHR-1 cells.
縮寫表I
中文摘要II
英文摘要IV
第一章 緒言
第二章 文獻探討
第一節 紅斑性狼瘡之簡介
第二節 紅斑性狼瘡相關之中草藥研究
第三節 紅斑性狼瘡之實驗動物
第四節 紅斑性狼瘡之免疫反應
第五節 紅斑性狼瘡腎炎
第三章 材料與方法
促進IL-2表現(IL-2 induction)試驗
抑制IL-2表現(inhibition of IL-2 expression)試驗 細胞增殖變化測定
實驗動物
小金英煎煮液之製備及冷凍乾燥
灌食保定
蛋白尿檢測
採血保定
介白素-2(IL-2)檢測
介白素-4(IL-4)檢測
丙型干擾素(interferon-γ)檢測
Anti-dsDNA抗體力價檢測
抗核抗體(ANA)力價檢測
抗核抗體分析
血清生化學檢測
實驗動物犧牲
石臘切片製作
蘇木紫與伊紅染色
Masson’s trichrome stain
Periodic acid schiff stain(PAS stain)
絲球體腎炎病變分級
冷凍切片之製作
組織免疫螢光染色
統計分析
第四章 結果
第一節 IL-2起動子之活性試驗
一、 促進IL-2表現(IL-2 induction)試驗
二、 抑制IL-2表現(inhibition of IL-2 expression)試驗
第二節 細胞增殖變化測定
第三節 NZB/NZW F1小鼠生長之影響
一、 實驗動物分組
二、 生長曲線
三、 對蛋白尿之影響
四、 生命期
第四節 對小鼠cytokines之影響
一、 介白素-2(IL-2)
二、 介白素-4(IL-4)
三、 丙型干擾素interferon-γ之影響
第五節 對小鼠自體抗體之影響
一、 Anti-dsDNA 抗體力價測定
二、 抗核抗體(ANA)力價測定
三、 西方墨漬法分析抗核抗體
第六節 小鼠血清生化學測定
第七節 小鼠絲球體腎炎病變分析
第五章 討論
參考文獻
吳文勉. 1995. 不同膳食油脂對自體免疫鼠NZB/NZW F1體內免疫細胞反應之影響. 國立台灣大學農業化學研究所碩士論文.
吳文勉. 2000. Study on therapeutic effects and regulatory Tamoxifen. 國立台灣大學醫學院微生物學研究所博士論文.
李蕙如. 2000. 人類白血球間素-2基因轉錄調節物質之篩選系統建立與測試. 國立陽明大學生命科學院藥理學研究所碩士論文.
沈明來. 1995. 試驗設計學. 眾光文化事業有限公司. 台灣台北.
高木村. 1999. 台灣民間藥(2). 南天書局. 台灣台北.
楊志良. 1992. 生物統計學新論. 巨流圖書公司. 台灣台北.
劉振軒、何逸遷、張文發、祝志平、王琇真. 1996. 組織病理染色技術與圖譜組織化學染色. 台灣養豬科學研究所. 台灣苗栗.
蔡寧遠. 1997. 家犬紅斑性狼瘡自體免疫抗體之研究. 國立中興大學獸醫學研究所碩士論文.
謝寶煖. 2000. 學術論文之註釋與參考書目. 國立中央圖書館臺灣分館館刊. 第六卷第三期:15-38.
Alcocer-Varela, J. and D.Alarcon-Segovia. 1982. Decreased production of and response to interleukin-2 by cultured lymphocytes from patients with systemic lupus erythematosus. J. Clin. Invest. 69: 1388- 1392.
Amital, H., Y. Levi, M. Blank, V. Barak, P. Langevitz, A. Afek, F. Nicoletti, J. Kopolovic, B. Gilburd, P. L. Meroni and Y. shoenfeld. 1998. Immunomodulation of murine experimental SLE-like diseas by interferon-γ. Lupus 7: 445- 454.
Andrews, B. S., R. A. Eisenberg, A. N. Theofilopoulos, S. Izui, C. B. Wilson, P. J. McConahey, E. D. Murphy, J. B. Roths and F. J. Dixon. 1978. Spontaneous murine lupus-like syndromes: clinical and immunolopathological manifestations in several strains. J. Exp. Med. 148: 1198- 1215.
Bono, L., J. S. Cameron and J. A. Hicks. 1999. The very long-term prognosis and complications of lupus nephritis and its treatment. Q J Med. 92: 211- 218
Bottazzo, G. F., B. R. Pujol and T. Hanafusa. 1983. Role of aberrant HLA-DR expression and antigen presentation in induction of endocrine autoimmunity. Lancet. 2: 1115- 1118.
Brenner, B. M. 1996. The Kidney 5th ed. W. B. Saunders Company, Philadelphia, U.S.A.
Buchman, A. L. 2001. Side effects of corticosteroid therapy. J Clin Gastroenterol. 33: 289- 294
Burnet, F. M., and M. C. Holmes. 1965. The natural history of the NZB/NZW F1 hybrid mouse: a laboratory model of systemic lupus erythematosus. Aust. Ann. Med. 14: 185- 191.
Chang, D. M., W. Y. Chang, S. Y. Kuo and M. L. Chang. 1997. The effects of traditional antirheumatic herbal medicines on immune response cells. J. Rheumatol. 24: 436- 441.
Chen, B. J. 2001. Triptolide, a novel immunosuppressive and anti-inflammatory agent purified from a Chinese herb Tripterygium wilfordii hook F. Leuk Lymphoma. 42: 253- 265.
Chen, J. R. , J. H. Yen, C. C. Lin, W. J. Tsai, W. J. Liu, J. J. Tsai, S. F. Lin and H. W. Liu. 1993. The effects of Chinese herbs on improving survival and inhibiting anti-ds DNA antibody production in Lupus mice. Am. J. of Chinese Med. 21: 257- 262.
Churg, J., J. Bernstein and R. J. Glassock. 1995. Renal Disease: Classification and Atlas of Glomerular Disease. 2nd ed. p. 151. Tokyo, New York, Igaku-Shoin.
Clark, W. F., A. Parbtani, M.W. Huff, B. Reid, B. J. Holub and P. Falardeau. 1989. Omega-3 fatty acid dietary supplementation in systemic lupus erythematosus. Kidney Int. 36: 653-660
Cotran, R. S., V. Kumar, S. L. Robbins and F. J Schoen. 1994. Robbins Pathologic Basis of Disease. 5th ed. Philadelphia, U. S. A.
Dobois, E. L. and D. J. Wallace. 1987. Management of discoid and systemic lupus erythematosus. In: Dubois’ Lupus Erythematosus. 3rd ed. Lea & Febiger. Philadelphia, U.S.A.
Donadio, J. V. Jr. and R. J. Glasock. 1993. Immunosuppressive drug therapy in lupus nephritis. Am. J. Kidney Dis. Mar. 21: 239-250.
Eros, E., P. Geher, B. Gomor and A. E. Czeizel. 1998. Epileptogenic activity of folic acid after drug induces SLE (folic acid and epilepsy). Eur. J. Obstet. Gynecol Repord. 80: 75-78.
Fessel, W. J. 1974. Systemic lupus erythematosus in the community. Incidence, prevalence, outcome, and first symptoms; the high prevalence in Black women. Arch. Intern. Med. 134: 1027-1035.
Furukawa, F. 1997. Animal models of cutaneous lupus erythematosus and lupus erythematosus photosensitivity. Lupus. 6: 193- 202.
Ghose, M. K. 1975. Pericardial tamponade. A presenting manifestation of procainamide-induced lupus erythematosus. Am. J. Med. 58: 581- 585.
Hase, K., K. Tani, T. Shimizu, Y. Ohmoto, K. Matsushima and S. Sone. 2001. Increased CCR4 expression in ac tive systemic lupus erythematosus. J. Leukoc. Biol. 70: 749- 755.
Hideo, K., S. Imamura, M. Takigawa and F. Furukawa. 1994. Evaluation of the Japanese-Chinese herbal Medicine, Kampo, for the treatment of lupus dermatoses in autoimmune prone MRL/Mp-lpr/lpr mice. J. Dermato. 21: 935- 939.
Howie, J. B. and B. J. Helyer. 1968. The immunology and pathology of NZB mice. Adv Immunol. 9: 215- 266.
Jones, B. M. 2001. Changes in cytokine production in healthy subjects practicing Guolin Qigong : a pilot study. BMC Complement Altern. Med. 1(1): 8.
Kanauchi, H., S. Imamura, M. Takigawa and F. Furukawa. 1994. Evaluation of the Japanese-Chinese herbal medicine, Kampo, for the treatment of Lupus dermatoses in autoimmune prone MRL/Mp-lpr/lpr mice. The J. of Dermatol. 21: 935- 939.
Kattwinkel, N., L. Cook and V. Agnello. 1991. Overwhelming fatal infection in a young woman after intravenous cyclophosphamide therapy for lupus nephritis. J. Rheumatol. 18: 79- 81.
Kelley, V. E., A. Ferretti, S. Izui and T. B. Strom. 1985. A fish oil diet rich in eicosapentaenoic acid reduces cyclooxygenase metabolites, and suppresses lupus in MRL-lpr mice. J. Immunol. 134: 1914- 1919.
Kuo, Y. C., C. M. Sun, W. J. Tsai, J. C. Ou, W. P. Chen and C. Y. Lin. 1998. Chinese herbs as modulators of human mesangial cell proliferation: preliminary studies. J. Lab. Clin. Med. 132: 76- 85.
Kuo, Y. C., J. C. Ou, W. J. Tsai, C. L. Wu and C. M. Sun. 1996. Evaluation of Chinese herbs that affect the cell-mediated immunity (II). J. Chin. Med. 7: 119- 131.
Kuo, Y. C., W. J. Tsai, M. S. H. Shiao, C. F. Chen and C. Y. Lin. 1996. Cordyceps sinensis as an immunomodulatory agent. American Jour. Chinese Med. XXIV (2): 111-125.
Lahita, R. G. 1992. Systemic Lupus Erythematosus. 2nd ed. Churchill Livingstone Inc. New York, U.S.A
Leiba, A., H. Amital, M. E. Gershwin and Y. Shoenfeld. 2001. Diet and lupus. Lupus. 10: 246- 248.
Lin, S.C., C. C. Lin, Y. H. Lin and C. J. Yao. 1994. Hepatoprotective effects of Taiwan folk medicine: Ixeris chinensis (Thumb) Nak.. on experimental liver injuries. Am. J. of Chinese Med. 12: 243- 254.
Ling, M. H. M., P. J. Perry and M. T. Tsaung. 1981. Side effects of corticosteroid therapy. Psychiatric aspects. Arch. Gen. Psychiatry. 38: 471-477.
Mansilla-Tinoco, R., S. J. Harland, P. J. Ryan, R. M. Bernstein, C. T. Dollery, G. R. Hughes, C. J. Bulpitt, A. Morgan and J. M. Jones. 1982. Hydralazine antinuclear antibodies and the lupus syndrome. Br. Med. J. 284: 936- 939.
Meleg-Smith, S. and N. K. Krane 2001/10/12. Clinico-Pathologic classification of Glomerular Disease. http://www.tmc.tulane.edu/classware/pathology/medical_pathology/New_for_2000/Renal/Renal.html#Clinical
Mosmann, T. 1983. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods. 65: 55- 63.
Ollier, W. and D. P. M. Symmons. 1992. Autoimmunity. BIOS Scientific Publisher Limited, Oxford. U. K. 9-15.
Patavino, T. 2001. Natural medicine and nutritional therapy as an alternative treatment in systemic lupus erythematosus. Altern. Med. Rev. 6: 460- 471.
Perkoff, G. T., R. Silber, F. H. Tyler et al. 1959. Studies in disorders of the muscle. XII. Myopathy due to the administration of therapeutic amounts of 17 hydroxy corticosteroids. Am. J. Med. 26: 891.
Perry, H. M. Jr. 1973. Late toxicity to hydralazine resembling systemic lupus erythematosus or rheumatoid arthritis. Am. J. Med. 54: 58- 72.
Perry, H. M. Jr., E. M. Tan, S. Carmody and A. Sakamota. 1970. Relationship of acetyl transferase activity to antinuclear antibodies and toxic symptoms in hypertensive patients treated with hydralazine. J. Lab. Clin. Med. 76: 114- 125.
Pine, J.W. 1997. Dubois’ Lupus Erythematosus. 5th ed. Editors, D. J. Wallace and H. H.Bevra; associated editors, Quismorio J. R. Klinenberg. U.S.A.
Pollak, V. E., C. L. Pirani and F. D. Schwartz. 1964. The natural history of renal manifestations of systemic lupus erythematosus. J. Lab. Clin. Med. 63: 537- 550.
Pritchard, N. R., A. J. Cutler, S. Uribe, S. J. Chadban, B. J. Morley and K. G. Smith. 2000. Autoimmune-prone mice share a promoter haplotype associated with reduced expression and function of the Fc receptor FcgammaRII. Curr. Biol. 10: 227- 230.
Schrier, B. W. 2001/10/20. Atlas of the diseases of Kidney. http://cnserver0.nkf.med.ualberta.ca/cn/Schrier/Volume4/chapter11/ADK4-11_7-9.pdf
Segal, R, B. L. Bermas, M Dayan, F. Kalush, G. M. Shearer and E. Mozes. 1997. Kinetics of cytokine production in experimental systemic lupus erythematosus: involvement of T helper cell 1/T helper cell 2-type cytokines in disease. J Immunol. 15; 158: 3009-16
Snowden, J. A., P. Kearney, A. Kearney, H. M. Cooley, A. Grigg, P. Jacobs, J. Bergman, P. M. Brooks and J. C. Biggs. 1998. Long-term outcome of autoimmune disease following allogeneic bone marrow transplantation. Arthritis Rheum. 41: 453-459.
Spiro, H. M. 1983. Is the steroid ulcer a myth? N. Engl. J. Med. 7; 309: 45- 47.
Takahashi, S., M. Nose, J. Sasaki, T. Yamamoto and M. Kyogoku. 1991. IgG3 production in MRL/lpr mice is responsible for development of lupus nephritis. J. Immunol. 147: 515-519.
Talal, N. 1974. Autoimmunity and lymphoid malignancy in New Zealand black mice. Prog. Clin. Immunol. 2: 101-120
Tanasescu, C. and S. Purice. 1992. Liver disease in systemic lupus erythematosus. Rom. J. Intern. Med. 30: 169-174
Utsinger, P. D., N. J. Zvaifler and H. G. Bluestein. 1976. Hypocomplementemia in procainamide-associated systemic lupus erythematosus. Ann. Intern. Med. 84: 293.
van Vollenhoven, R. F., L. M. Morabito, E. G. Engleman and J. L. McGuire. 1998. Treatment of systemic lupus erythematosus with dehydroepiandrosterone : 50 patients treated for up to 12 months. J. Rheumatol. 25: 285-289.
Varey, A. M., P. M. Lydard and B. M. Dean. 1988. Interferon gamma induces islet cell class II MHC antigens on RINm5F cells. Diabetes. 37: 209- 212.
Walker, R., A. Cooke and A. J. Bone. 1986. Induction of class II MHC antigens in vitro on pancreatic β-cell in the NOD mouse. Diabetologia. 30: 104- 108.
Weiner, E. S. and M. Abeles. 1990. More on aseptic necrosis and glucocorticoids in systemic lupus erythematosus. J. Rheumatol. 17:119.
Weisman, M. H., H. G. Bluestein, C. M. Berner and H. A. de Haan. 1997. Reduction in circulating dsDNA antibody titer after administration of LJP394. J. Rheumatol. 24:314-318
Yang, L. Y., A. Chen, Y. C. Kuo and C. Y. Lin. 1999. Efficacy of a pure compound H1-A extracted from Cordyceps sinensis on autoimmune disease of MRL lpr/lpr mice. J. Lab. Clin Med. 134: 492- 500.
Yang, N. S., C. J. Chou, L. C. Lin, W. J. Tsai and Y. C. Kuo. 1999. Evaluation of Chinese herbs that affect the cell-mediated immunity(III). J. Chin. Med. 10: 179- 188.
Yap, H. K., S. G Ang, Y. H. Lai, V. Ramgolam and S. C. Jordan. 1999. Improvement in lupus nephritis following treatment with a Chinese herbal preparation. Arch. Pediatr. Adolesc. Med. 153: 850- 852.
Yoh, K., I. Ken, A. Enomoto, A. Hirayama, N. Yamaguchi, M. Kobayashi, N. Morito, A. Koyama, M. Yamamoto and S. Takahashi. 2001. Nrf2-deficient female mice develop lupus-like autoimmune nephritis. Kidney International. 60: 1343-1353.
Yu, D. 1983. Clinical observation of 144 cases of rheumatoid arthritis treated with glycosides of Tripterygium wilfordii. J. Tradit. Clin. Med. 3: 125-9.
Zan-Bar, I., S. Slavin and S. Strober. 1978. Induction and mechanism of tolerance to bovine serum albumen in mice given total lymphoid irradiation (TLI). J. Immunol. 121: 1400- 1404.
Zhang, X. Y., N. Tsuchiya, M. Dohi, K. Yamamoto, K. Ishihara, H. Okudaira, K. Ito and T. Miyamoto. 1992. Prolonged survival of MRL-lpr/lpr mice treated with Tripterygium wilfordii Hook-F. Clin. Immunol. Immunopathol. 62: 66- 71.
QRCODE
 
 
 
 
 
                                                                                                                                                                                                                                                                                                                                                                                                               
第一頁 上一頁 下一頁 最後一頁 top